Flag of the European Union EU Clinical Trials Register Help

Clinical trials for No treatment

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

  • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).


    The EU Clinical Trials Register currently displays   44358   clinical trials with a EudraCT protocol, of which   7384   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    34,451 result(s) found for: No treatment. Displaying page 187 of 1,723.
    EudraCT Number: 2005-003251-13 Sponsor Protocol Number: D1449L00002 Start Date*: 2005-10-20
    Sponsor Name:AstraZeneca UK Ltd
    Full Title: Quetiapine Augmentation In Treatment-Resistant Depression – An Open Pilot Study
    Medical condition: Depression
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2004-004796-11 Sponsor Protocol Number: CZOL446GDE24 Start Date*: 2007-08-14
    Sponsor Name:Klinikum Augsburg
    Full Title: An Open-Label, Non-Randomized, Single center Study to Evaluate the Use of Zoledronic Acid in the Prevention of Cancer Treatment-Related Bone Loss in Postmenopausal Women with ER+ and/or PgR+ Breast...
    Medical condition: Prevention of cancer treatment-related bone loss in postmenopausal women with resected stage I-IIIa hormone receptor positive breast cancer, who will receive letrozole as adjuvant therapy.
    Disease:
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: DE (Completed)
    Trial results: (No results available)
    EudraCT Number: 2004-001083-43 Sponsor Protocol Number: BAY 59-7939 / 11223 Start Date*: 2004-11-23
    Sponsor Name:Bayer HealthCare AG
    Full Title: Oral Direct Factor Xa Inhibitor BAY 59-7939 in Patients with acute symptomatic Deep Vein Thrombosis ODIXa-DVT A prospective, randomized, multinational, multicenter, partially blinded, parallel-grou...
    Medical condition: Acute deep vein thrombosis
    Disease: Version SOC Term Classification Code Term Level
    7.0 10051055 Code
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: HU (Completed) GB (Completed)
    Trial results: View results
    EudraCT Number: 2009-014580-39 Sponsor Protocol Number: SP-B-02 Start Date*: 2010-01-05
    Sponsor Name:ALK-Abelló Arzneimittel GmbH
    Full Title: A multicentre randomised Phase II clinical pilot study to compare the pharmacodynamic efficacy and tolerability of the sublingual and the vestibular administration route for SLITonePLUS® Birch
    Medical condition: Birch pollen induced allergic rhinoconjunctivitis requiring treatment during the birch pollen season
    Disease: Version SOC Term Classification Code Term Level
    12.0 10001728 Allergic rhinoconjunctivitis LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: View results
    EudraCT Number: 2009-018005-43 Sponsor Protocol Number: 205.419 Start Date*: 2010-06-14
    Sponsor Name:Boehringer Ingelheim Pharma GmbH & Co. KG
    Full Title: A Phase III randomised, double-blind, placebo-controlled, parallel-group trial to evaluate efficacy and safety of tiotropium inhalation solution delivered via Respimat® inhaler (2.5 and 5 μg once ...
    Medical condition: Moderate persistent asthma
    Disease: Version SOC Term Classification Code Term Level
    14.1 10038738 - Respiratory, thoracic and mediastinal disorders 10003553 Asthma PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) PL (Completed)
    Trial results: View results
    EudraCT Number: 2013-003239-31 Sponsor Protocol Number: HOVIR_700 Start Date*: 2014-03-14
    Sponsor Name:HOV GmbH
    Full Title: A randomised, placebo-controlled, single-centre, double-blind study to evaluate the efficacy, safety and tolerability of topically applied piroxicam gel in patients with recurrent herpes labialis
    Medical condition: Recurrent Herpes labialis
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: DE (Temporarily Halted)
    Trial results: (No results available)
    EudraCT Number: 2010-019411-37 Sponsor Protocol Number: FE999906CS11 Start Date*: 2010-08-30
    Sponsor Name:FERRING Arzneimittel GmbH
    Full Title: A Prospective, Open Label, Randomised, Parallel Group Trial Comparing the Effects of Highly Purified Menotrophin and Recombinant Follicle Stimulating Hormone (rFSH, Follitropin alpha) Administered ...
    Medical condition: Controlled ovarian hyperstimulation to induce the development of multiple follicles for assisted reproductive technologies
    Disease: Version SOC Term Classification Code Term Level
    14.0 10038604 - Reproductive system and breast disorders 10021926 Infertility PT
    Population Age: Adults Gender: Female
    Trial protocol: DE (Completed)
    Trial results: View results
    EudraCT Number: 2011-004579-35 Sponsor Protocol Number: A3921095 Start Date*: 2012-05-01
    Sponsor Name:Pfizer Inc, 235 East 42nd Street, New York, New York 10017
    Full Title: A MULTICENTRE, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL-GROUP STUDY OF ORAL CP-690,550 AS AN INDUCTION THERAPY IN SUBJECTS WITH MODERATE TO SEVERE ULCERATIVE COLITIS
    Medical condition: Moderate to severe active Ulcerative Colitis
    Disease: Version SOC Term Classification Code Term Level
    17.1 100000004856 10045365 Ulcerative colitis LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed) CZ (Completed) HU (Completed) EE (Completed) DK (Completed) LV (Completed) BE (Completed) ES (Completed) NL (Completed) AT (Completed) DE (Completed) SK (Completed) PL (Completed) HR (Completed)
    Trial results: View results
    EudraCT Number: 2011-005542-35 Sponsor Protocol Number: CRFB002DDE21 Start Date*: 2012-05-08
    Sponsor Name:Novartis Pharma GmbH
    Full Title: Multicenter randomized open-label three-arms controlled 12 months clinical proof of concept study to evaluate efficacy and safety of Ranibizumab alone or in combination with laser photocoagulation ...
    Medical condition: Proliferative diabetic retinopathy
    Disease: Version SOC Term Classification Code Term Level
    18.1 100000004853 10036857 Proliferative diabetic retinopathy LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: View results
    EudraCT Number: 2011-004775-36 Sponsor Protocol Number: DETOX-11 Start Date*: 2012-01-30
    Sponsor Name:GET SRL
    Full Title: ''A Phase III, multicenter, open-label study, to evaluate the efficacy and safety of different dosage regimens of 0.2 mg lofexidine hydrochloride (DIMATEX) in the treatment of withdrawal symptoms d...
    Medical condition: Oppiate addicts(heroin, methadone and buprenorphine)
    Disease: Version SOC Term Classification Code Term Level
    14.1 10037175 - Psychiatric disorders 10032707 Other specified drug dependence, continuous use LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: IT (Completed)
    Trial results: View results
    EudraCT Number: 2015-004455-52 Sponsor Protocol Number: CP15/15 Start Date*: 2016-04-18
    Sponsor Name:Cipla Europe NV
    Full Title: An open label, prospective, randomized, parallel group, multicenter 4-week study to evaluate the efficacy and safety of salmeterol/ fluticasone propionate fixed dose combination following ...
    Medical condition: Asthma
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: DE (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2018-002650-67 Sponsor Protocol Number: IBERepic/2018 Start Date*: 2018-11-15
    Sponsor Name:Ibermutuamur (Mutua Colaboradora con la Seguridad Social nº 274)
    Full Title: Comparison of the efficacy of autologous platelet rich plasma injections, and extracorporeal shock wave therapy, in the treatment of work –related lateral epicondylitis.
    Medical condition: The epicondylitis is an overuse injury, in most cases, is a self-limited course and responds well to conservative treatment. Its etiology is degenerative and is related to a repetitive overuse and ...
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: ES (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2004-002473-23 Sponsor Protocol Number: B9E-XM-O421 Start Date*: 2005-03-24
    Sponsor Name:Dr. Amalia Velasco
    Full Title: PHASE II TRIAL OF THE SEQUENTIAL ADMINISTRATION OF COMBINATIONS OF GEMCITABINE-CISPLATIN AND CARBOPLATIN-PACLITAXEL FOR THE TREATMENT OF PATIENTS WITH ADVANCED CARCINOMA OF THE OVARY WITH SUB-OPT...
    Medical condition: The Phase II trial will be performed on a population of patients with a histological or cytological diagnosis of ovarian cancer (any histological type), at stages IIIB, IIIC, IV or primary peritone...
    Disease:
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: ES (Completed)
    Trial results: (No results available)
    EudraCT Number: 2008-003230-22 Sponsor Protocol Number: CICL670AIT07 Start Date*: 2008-11-04
    Sponsor Name:NOVARTIS FARMA
    Full Title: Multicenter, open label, prospective study to evaluate the efficacy and safety of deferasirox 30 mg/kg/day for 52 weeks, in transfusion-dependent β-thalassemic patients with cardiac MRI ...
    Medical condition: cardiac iron overload
    Disease: Version SOC Term Classification Code Term Level
    9.1 10019024 Haemosiderosis LLT
    Population Age: Children, Adolescents, Under 18, Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Completed)
    Trial results: View results
    EudraCT Number: 2008-007515-33 Sponsor Protocol Number: Mel-Swe-01 Start Date*: 2009-08-13
    Sponsor Name:SentoClone AB
    Full Title: A multi-centre, two-arm, randomized, open, phase II study of adaptive design investigating SentoClone® compared to reference treatment in advanced malignant melanoma
    Medical condition: Surgically incurable stage III or IV malignant melanoma.
    Disease: Version SOC Term Classification Code Term Level
    9.1 10025670 Malignant melanoma stage III PT
    9.1 10025671 Malignant melanoma stage IV LLT
    Population Age: Children, Adolescents, Under 18, Adults, Elderly Gender: Male, Female
    Trial protocol: SE (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2007-001114-17 Sponsor Protocol Number: WA19923 Start Date*: 2007-12-12
    Sponsor Name:F. Hoffmann-La Roche Limited
    Full Title: A Mechanism of Action study to evaluate the effects of IL-6 receptor blockade with tocilizumab (TCZ) on lipids, arterial stiffness, and markers of atherogenic risk in patients with moderate to seve...
    Medical condition: Rheumatoid Arthritis (RA)
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: Removed from public view
    EudraCT Number: 2010-022166-27 Sponsor Protocol Number: CBGG492A2210 Start Date*: 2010-11-29
    Sponsor Name:Novartis Pharma Services AG
    Full Title: A multicenter, randomized, double-blind, placebo- controlled, cross-over, proof of concept study comparing the effects of both single dose and repeated dosing treatment for 2 weeks of BGG492 in p...
    Medical condition: indication “tinnitus”. condition: patients with chronic subjective tinnitus.
    Disease: Version SOC Term Classification Code Term Level
    14.1 10013993 - Ear and labyrinth disorders 10043882 Tinnitus PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) NL (Completed)
    Trial results: View results
    EudraCT Number: 2013-000241-39 Sponsor Protocol Number: BAY86-9766/16728 Start Date*: 2013-07-26
    Sponsor Name:Bayer HealthCare AG
    Full Title: A prospective, single-arm, multicenter, uncontrolled, open-label Phase II trial of refametinib (BAY 86-9766) in combination with sorafenib as first line treatment in patients with RAS mutant Hepato...
    Medical condition: KRAS or NRAS mutant unresectable or metastatic Hepatocellular carcinoma (HCC)
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: AT (Completed) CZ (Completed) GB (Completed) DE (Completed) BE (Completed) IT (Completed) HU (Completed) ES (Completed)
    Trial results: View results
    EudraCT Number: 2008-008376-14 Sponsor Protocol Number: COD_REG_46_DGR _13751_07 Start Date*: 2009-02-24
    Sponsor Name:AZIENDA ASL BRESCIA
    Full Title: A PLACEBO-CONTROLLED, DOUBLE-BLIND, RANDOMIZED TRIAL TO INVESTIGATE EFFICACY AND SAFETY OF COMBINED TREATMENT OF GUGGULU AND TRIPHALA FOR THE TREATMENT OF HYPERCHOLESTEROLEMIA AND OVERWEIGHT IN SUB...
    Medical condition: high blood cholesterol overweight
    Disease: Version SOC Term Classification Code Term Level
    9.1 10020602 Hypercholesteremia LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: IT (Completed)
    Trial results: (No results available)
    EudraCT Number: 2010-020973-18 Sponsor Protocol Number: L00006CP405 Start Date*: 2011-03-01
    Sponsor Name:PIERRE FABRE MEDICAMENT
    Full Title: “Effect of treatment with ossein-hydroxyapatite compound on the time of fracture-healing”. A prospective, multicenter, double-blind, randomised, placebo controlled clinical trial.
    Medical condition: Wrist fracture
    Disease: Version SOC Term Classification Code Term Level
    14.0 10042613 - Surgical and medical procedures 10061959 Fracture treatment PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: PL (Completed)
    Trial results: View results
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Sun Sep 07 21:51:01 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA